Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma

Article Chemistry, Medicinal

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment

Lu Turkovic et al.

Summary: A novel bioanalytical LC-ESI-MS/MS method was developed for the quantitation of six breast cancer chemotherapeutic drugs in human plasma. The method was validated and successfully applied to patient samples.

PHARMACEUTICALS (2022)

Add to Collection

Article Oncology

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

S. L. Groenland et al.

Summary: Pharmacokinetically guided dose optimization of oral targeted therapies is feasible in clinical practice and significantly reduces the proportion of underexposed patients.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Biochemical Research Methods

Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS

Yu Sato et al.

Summary: A novel liquid chromatography/electrospray ionization tandem mass spectrometry method was developed for the simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and the estrogen receptor antagonist. The method showed good accuracy and stability, making it suitable for therapeutic drug monitoring and pharmacokinetics/pharmacodynamics research in anticancer drugs.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)

Add to Collection

Article Oncology

Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3

Hiroji Iwata et al.

Summary: The most common treatment-related adverse event in clinical trials with the CDK4/6 inhibitor palbociclib is neutropenia. Low baseline absolute neutrophil count was identified as a strong independent risk factor for grade 3/4 neutropenia, and genetic variants in ABCB1 and ERCC1 may play a role in its occurrence. Pharmacogenetic testing could inform clinicians about the likelihood of severe neutropenia with palbociclib.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Harold J. Burstein et al.

Summary: This study updated the treatment guidelines for hormone receptor (HR)-positive metastatic breast cancer, highlighting the importance of Alpelisib in combination with endocrine therapy, PIK3CA mutation testing, drug selection for BRCA1 or BRCA2 mutation carriers, and the use of CDK4/6 inhibitors in different patient populations.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Biochemical Research Methods